CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 1st AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT by...License and Collaboration Agreement • May 7th, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations
THIS 1st AMENDMENT to the LICENSE AND COLLABORATION AGREEMENT (this “Amendment”), entered into as of January 2, 2024 (the “Amendment Effective Date”), is entered into by and between Daiichi Sankyo Company, Limited, a company organized and existing under the laws of Japan (“DS”) and Esperion Therapeutics, Inc., a corporation organized and existing under the laws of the state of Delaware (“Esperion”). DS and Esperion are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL SETTLEMENT AGREEMENT AND RELEASESettlement Agreement • May 7th, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations • New York
This Confidential Settlement Agreement and Release (the “Settlement Agreement”) is made and entered into as of January 2, 2024 (the “SA Effective Date”) between Esperion Therapeutics, Inc. (“Esperion”), a Delaware corporation with offices at 3891 Ranchero Drive, Suite 150, Ann Arbor, Michigan, USA 48108, and Daiichi Sankyo Europe GmbH (“DSE”), a company with limited liability incorporated under German law with offices at Zielstattstr 48, 81379 Munich, Germany. Esperion and DSE may each be referred to herein individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***] HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 3rd AMENDMENT TO THE LICENSE AND COLLABORATION AGREEMENT by...License and Collaboration Agreement • May 7th, 2024 • Esperion Therapeutics, Inc. • Pharmaceutical preparations
THIS 3rd AMENDMENT to the LICENSE AND COLLABORATION AGREEMENT (this “3rd Amendment”), entered into as of January 2, 2024 (the “3rd Amendment Effective Date”), is entered into by and between Daiichi Sankyo Europe GmbH, a corporation organized and existing under the laws of Germany (“DSE”) and Esperion Therapeutics, Inc., a corporation organized and existing under the laws of the state of Delaware (“Esperion”). DSE and Esperion are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
